Estos datos refuerzan el inters teraputico por los anlogos GLP-1, pero tambin alertan sobre la necesidad de usarlos con rigor y con un seguimiento clnico exhaustivo, tal y como expone el mdico de familia Ermengol Sempere Verd en un nuevo episodio de Pldoras de ciencia en abierto
The American Diabetes Association (ADA) Standards of Care recommend GLP-1 receptor agonists with proven cardiovascular benefit for patients with established atherosclerotic cardiovascular disease or high cardiovascular risk, regardless of A1C 5
10.3390/ijms17071134 74
Labeling them as carcinoids or, worse, well-differentiated neuroendocrine carcinomas, is confusing, particularly to clinicians, and is only marginally supported morphologically
Beyond Weight: Other GLP-1 Research Areas GLP-1 receptor agonism has demonstrated effects beyond weight and glucose in preclinical and clinical research: Cardiovascular protection , GLP-1 RAs reduce MACE (major adverse cardiovascular events) in high-risk type 2 diabetes populations
doi: 10.1007/s11011-018-0224-4 226 MirzaAForbesJDZhuFBernsteinCNVan DomselaarGGrahamMet al